BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33892273)

  • 1. Progress in developing MNK inhibitors.
    Jin X; Yu R; Wang X; Proud CG; Jiang T
    Eur J Med Chem; 2021 Jul; 219():113420. PubMed ID: 33892273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MAP kinase-interacting kinases regulate cell migration, vimentin expression and eIF4E/CYFIP1 binding.
    Beggs JE; Tian S; Jones GG; Xie J; Iadevaia V; Jenei V; Thomas G; Proud CG
    Biochem J; 2015 Apr; 467(1):63-76. PubMed ID: 25588502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Mitogen-activated Protein Kinase (MAPK)-interacting Kinase (MNK) Preferentially Affects Translation of mRNAs Containing Both a 5'-Terminal Cap and Hairpin.
    Korneeva NL; Song A; Gram H; Edens MA; Rhoads RE
    J Biol Chem; 2016 Feb; 291(7):3455-67. PubMed ID: 26668315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno[2,3-d]pyrimidine scaffold.
    Jin X; Merrett J; Tong S; Flower B; Xie J; Yu R; Tian S; Gao L; Zhao J; Wang X; Jiang T; Proud CG
    Eur J Med Chem; 2019 Jan; 162():735-751. PubMed ID: 30496989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors.
    Dreas A; Mikulski M; Milik M; Fabritius CH; Brzózka K; Rzymski T
    Curr Med Chem; 2017; 24(28):3025-3053. PubMed ID: 28164761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines.
    Ramalingam S; Gediya L; Kwegyir-Afful AK; Ramamurthy VP; Purushottamachar P; Mbatia H; Njar VC
    Oncotarget; 2014 Jan; 5(2):530-43. PubMed ID: 24504069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis and Evaluation of Novel Phorbazole C Derivatives as MNK Inhibitors through Virtual High-Throughput Screening.
    Jin X; Li M; Qiu T; Yu R; Jiang T
    Mar Drugs; 2022 Jun; 20(7):. PubMed ID: 35877722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.
    Reich SH; Sprengeler PA; Chiang GG; Appleman JR; Chen J; Clarine J; Eam B; Ernst JT; Han Q; Goel VK; Han EZR; Huang V; Hung INJ; Jemison A; Jessen KA; Molter J; Murphy D; Neal M; Parker GS; Shaghafi M; Sperry S; Staunton J; Stumpf CR; Thompson PA; Tran C; Webber SE; Wegerski CJ; Zheng H; Webster KR
    J Med Chem; 2018 Apr; 61(8):3516-3540. PubMed ID: 29526098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
    Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
    Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
    Liu Y; Sun L; Su X; Guo S
    Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development.
    Ueda T; Watanabe-Fukunaga R; Fukuyama H; Nagata S; Fukunaga R
    Mol Cell Biol; 2004 Aug; 24(15):6539-49. PubMed ID: 15254222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAP kinase-interacting kinases--emerging targets against cancer.
    Diab S; Kumarasiri M; Yu M; Teo T; Proud C; Milne R; Wang S
    Chem Biol; 2014 Apr; 21(4):441-452. PubMed ID: 24613018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probing the binding mechanism of Mnk inhibitors by docking and molecular dynamics simulations.
    Kannan S; Poulsen A; Yang HY; Ho M; Ang SH; Eldwin TS; Jeyaraj DA; Chennamaneni LR; Liu B; Hill J; Verma CS; Nacro K
    Biochemistry; 2015 Jan; 54(1):32-46. PubMed ID: 25431995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Regulation of ZEB1 and EMT by MAPK-Interacting Protein Kinases (MNK) and eIF4E in Pancreatic Cancer.
    Kumar K; Chow CR; Ebine K; Arslan AD; Kwok B; Bentrem DJ; Eckerdt FD; Platanias LC; Munshi HG
    Mol Cancer Res; 2016 Feb; 14(2):216-27. PubMed ID: 26609108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of eukaryotic initiation factor 4E (eIF4E) phosphorylation by mitogen-activated protein kinase occurs through modulation of Mnk1-eIF4G interaction.
    Shveygert M; Kaiser C; Bradrick SS; Gromeier M
    Mol Cell Biol; 2010 Nov; 30(21):5160-7. PubMed ID: 20823271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E.
    Li Y; Yue P; Deng X; Ueda T; Fukunaga R; Khuri FR; Sun SY
    Neoplasia; 2010 Oct; 12(10):848-55. PubMed ID: 20927323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation of the mRNA cap-binding protein eIF4E and cancer.
    Yang X; Zhong W; Cao R
    Cell Signal; 2020 Sep; 73():109689. PubMed ID: 32535199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.
    Abdelaziz AM; Diab S; Islam S; Basnet SKC; Noll B; Li P; Mekonnen LB; Lu J; Albrecht H; Milne RW; Gerber C; Yu M; Wang S
    Med Chem; 2019; 15(6):602-623. PubMed ID: 30569866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mnk inhibitors: a patent review.
    Abdelaziz AM; Yu M; Wang S
    Pharm Pat Anal; 2021 Jan; 10(1):25-35. PubMed ID: 33441033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.
    Lim S; Saw TY; Zhang M; Janes MR; Nacro K; Hill J; Lim AQ; Chang CT; Fruman DA; Rizzieri DA; Tan SY; Fan H; Chuah CT; Ong ST
    Proc Natl Acad Sci U S A; 2013 Jun; 110(25):E2298-307. PubMed ID: 23737503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.